nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

08.01.2016 | Original Article – Cancer Research

Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma

verfasst von: Steffen Rausch, Jörg Hennenlotter, Marcus Scharpf, Katharina Teepe, Ursula Kühs, Stefan Aufderklamm, Simone Bier, Johannes Mischinger, Georgios Gakis, Arnulf Stenzl, Christian Schwentner, Tilman Todenhöfer

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine the expression patterns of the proliferation marker prostate tumor overexpressed 1 (PTOV1) in invasive urothelial cancer (UC).

Methods

Corresponding UC and benign samples from paraffin-embedded tissue of 102 patients treated with cystectomy for invasive UC were immunohistochemically (IHC) assessed for PTOV1. Expression was evaluated gradually separated for cytoplasmic and nuclear staining. Results were correlated to histological and clinical data. To correlate PTOV1 expression with molecular subtypes of UC, analysis of PTOV1 RNA expression data of the Cancer Genome Atlas UC cohort was performed.

Results

PTOV1 expression was present in UC and benign urothelium, whereby nuclear staining was significantly more frequent in UC tissue (p = 0.0004). Lower cytoplasmic expression was significantly associated with pathological stage >pT2 (p = 0.0014) and grade ≥G3 (p = 0.0041), respectively. IHC expression patterns did not show correlation to survival data. PTOV1 RNA expression correlated with features of the luminal UC subtype.

Conclusions

Subcellular distribution seems to be the most important feature of PTOV1 expression in UC. Nuclear localization of PTOV1 along with cytoplasmic decrease in PTOV1 expression was identified as putative surrogate for PTOV1-associated cellular proliferation and dedifferentiation in UC. The functional relevance as well as the potential role of PTOV1 as a biomarker in UC remains to be specified in future studies.

Alana L et al (2014) Prostate tumor overexpressed-1 (PTOV1) down-regulates HES1 and HEY1 notch targets genes and promotes prostate cancer progression. Mol Cancer 13:74. doi:10.1186/1476-4598-13-74 CrossRefPubMedPubMedCentral

Benedit P et al (2001) PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology blocks. Oncogene 20:1455–1464. doi:10.1038/sj.onc.1204233 CrossRefPubMed

Benzinger A, Muster N, Koch HB, Yates JR III, Hermeking H (2005) Targeted proteomic analysis of 14-3-3 sigma, a p53 effector commonly silenced in cancer. Mol Cell Proteomics (MCP) 4:785–795. doi:10.1074/mcp.M500021-MCP200 CrossRef

Bertz S et al (2014) Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. Eur Urol 65:218–226. doi:10.1016/j.eururo.2012.05.033 CrossRefPubMed

Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315–322. doi:10.1038/nature12965 CrossRef

Chen SP, Zhang LS, Fu BS, Zeng XC, Yi HM, Jiang N (2015) Prostate tumor overexpressed 1 is a novel prognostic marker for hepatocellular carcinoma progression and overall patient survival. Medicine 94:e423. doi:10.1097/MD.0000000000000423 CrossRefPubMedPubMedCentral

Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, McConkey DJ (2014a) Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer Nature reviews. Urology 11:400–410. doi:10.1038/nrurol.2014.129 PubMed

Choi W et al (2014b) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152–165. doi:10.1016/j.ccr.2014.01.009 CrossRefPubMedPubMedCentral

Damrauer JS et al (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA 111:3110–3115. doi:10.1073/pnas.1318376111 CrossRefPubMedPubMedCentral

Ferlay J et al (2015) Reprint of: cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 51:1201–1202. doi:10.1016/j.ejca.2015.05.004 CrossRef

Fernandez S et al (2011) PTOV1 is overexpressed in human high-grade malignant tumors. Virchows Archiv Int J Pathol 458:323–330. doi:10.1007/s00428-010-1018-1 CrossRef

Guo F, Feng L, Hu JL, Wang ML, Luo P, Zhong XM, Deng AM (2015) Increased PTOV1 expression is related to poor prognosis in epithelial ovarian cancer. Tumour Biol J Int Soc Oncodev Biol Med 36:453–458. doi:10.1007/s13277-014-2662-x CrossRef

Hard RL, Liu J, Shen J, Zhou P, Pei D (2010) HDAC6 and Ubp-M BUZ domains recognize specific C-terminal sequences of proteins. Biochemistry 49:10737–10746. doi:10.1021/bi101014s CrossRefPubMedPubMedCentral

Kirkali Z et al (2005) Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66:4–34. doi:10.1016/j.urology.2005.07.062 CrossRefPubMed

Lei F, Zhang L, Li X, Lin X, Wu S, Li F, Liu J (2014) Overexpression of prostate tumor overexpressed 1 correlates with tumor progression and predicts poor prognosis in breast cancer. BMC Cancer 14:457. doi:10.1186/1471-2407-14-457 CrossRefPubMedPubMedCentral

Li M et al (2015) Overexpression of HMGB3 protein promotes cell proliferation, migration and is associated with poor prognosis in urinary bladder cancer patients. Tumour Biol J Int Soc Oncodev Biol Med. doi:10.1007/s13277-015-3130-y

Lotan Y et al (2013) Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. Eur Urol 64:465–471. doi:10.1016/j.eururo.2013.03.043 CrossRefPubMed

Mangrud OM et al (2014) Prognostic comparison of proliferation markers and World Health Organization 1973/2004 grades in urothelial carcinomas of the urinary bladder. Hum Pathol 45:1496–1503. doi:10.1016/j.humpath.2014.03.001 CrossRefPubMed

Marques N et al (2014) Regulation of protein translation and c-Jun expression by prostate tumor overexpressed 1. Oncogene 33:1124–1134. doi:10.1038/onc.2013.51 CrossRefPubMed

Mazzucchelli R, Barbisan F, Santinelli A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R (2011) Immunohistochemical expression of prostate tumor overexpressed 1 in cystoprostatectomies with incidental and insignificant prostate cancer. Further evidence for field effect in prostatic carcinogenesis Human pathology 42:1931–1936. doi:10.1016/j.humpath.2011.02.014 PubMed

McConkey DJ, Choi W, Dinney CP (2015) Genetic subtypes of invasive bladder cancer. Curr Opin Urol 25:449–458. doi:10.1097/MOU.0000000000000200 CrossRefPubMed

Morote J et al (2008) PTOV1 expression predicts prostate cancer in men with isolated high-grade prostatic intraepithelial neoplasia in needle biopsy. Clin Cancer Res 14:2617–2622. doi:10.1158/1078-0432.CCR-07-4987 CrossRefPubMed

Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138–140PubMed

Santamaria A et al (2005) PTOV1 enables the nuclear translocation and mitogenic activity of flotillin-1, a major protein of lipid rafts. Mol Cell Biol 25:1900–1911. doi:10.1128/MCB.25.5.1900-1911.2005 CrossRefPubMedPubMedCentral

Shariat SF et al (2006) Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 176:2414–2422. doi:10.1016/j.juro.2006.08.004 (discussion 2422) CrossRefPubMed

Witjes JA et al (2014) EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 65:778–792. doi:10.1016/j.eururo.2013.11.046 CrossRefPubMed

Titel: Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma
verfasst von: Steffen Rausch
Jörg Hennenlotter
Marcus Scharpf
Katharina Teepe
Ursula Kühs
Stefan Aufderklamm
Simone Bier
Johannes Mischinger
Georgios Gakis
Arnulf Stenzl
Christian Schwentner
Tilman Todenhöfer
Publikationsdatum: 08.01.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 5/2016
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-015-2107-y

Springer Medizin

Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma